BioLineRx Ltd.

DB:YP2A Stock Report

Market Cap: €16.2m

BioLineRx Management

Management criteria checks 3/4

BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 8.25 years. total yearly compensation is $952.00K, comprised of 29.4% salary and 70.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth €2.32K. The average tenure of the management team and the board of directors is 8.1 years and 3.1 years respectively.

Key information

Phil Serlin

Chief executive officer

US$952.0k

Total compensation

CEO salary percentage29.4%
CEO tenure8.3yrs
CEO ownership0.01%
Management average tenure8.1yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Phil Serlin's remuneration changed compared to BioLineRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$49m

Dec 31 2023US$952kUS$280k

-US$61m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$32m

Dec 31 2022US$1mUS$297k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$903kUS$290k

-US$27m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$958kUS$250k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$678kUS$256k

-US$25m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$846kUS$254k

-US$23m

Compensation vs Market: Phil's total compensation ($USD952.00K) is above average for companies of similar size in the German market ($USD462.70K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Serlin (64 yo)

8.3yrs

Tenure

US$952,000

Compensation

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leadership Team

NamePositionTenureCompensationOwnership
Philip Serlin
Chief Executive Officer8.3yrsUS$952.00k0.014%
€ 2.3k
Mali Zeevi
Chief Financial Officer8.3yrsUS$443.00k0.027%
€ 4.4k
Ella Sorani
Chief Development Officer7.9yrsUS$520.00k0.0055%
€ 893.6
John Lacey
Head of Corporate Communications & Investor Relationsno datano datano data
Tsipi Keren-Lehrer
Head of BD & Strategic Advisor5.4yrsno datano data
Raziel Fried
Treasurer & Budgetary Control Directorno datano datano data

8.1yrs

Average Tenure

56yo

Average Age

Experienced Management: YP2A's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aharon Schwartz
Chairman of the Board21yrsno data0.31%
€ 50.1k
Sandra Panem
Director10.9yrsno datano data
Avraham Molcho
Independent External Director14.5yrsUS$26.55kno data
Raphael Hofstein
Director22yrsUS$140.92kno data
Ronald Levy
Member of Immuno-Oncology Scientific Advisory Board3.1yrsno datano data
Rami Dar
Independent External Director2.5yrsno datano data
Gal Cohen
Independent Director1.1yrsno datano data
Barbar-Jean Bormann-Kennedy
Director11.4yrsno datano data
Jon Marc Wigginton
Member of Immuno-Oncology Scientific Advisory Board3.1yrsno datano data
Ignacio Melero Bermejo
Member of Immuno-Oncology Scientific Advisory Board3.1yrsno datano data
Aurelien Marabelle
Member of Immuno-Oncology Scientific Advisory Board3.1yrsno datano data
Shaoyu Yan
Director1.2yrsno datano data

3.1yrs

Average Tenure

66yo

Average Age

Experienced Board: YP2A's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 05:37
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioLineRx Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Joseph PantginisH.C. Wainwright & Co.
Michael KingJMP Securities